Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rastelli

Showing results (661-670 of 680) with videos related to

Pageof 68
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Molecules (Basel, Switzerland)|January 8, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6Jean Jacques Vanden Eynde, Arduino A Mangoni, Jarkko Rautio, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 68

Showing results (661-670 of 680) with videos related to

Sort By:
Pageof 68
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Molecules (Basel, Switzerland)|January 8, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6Jean Jacques Vanden Eynde, Arduino A Mangoni, Jarkko Rautio, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 68